We narrowed to 35,467 results for: LAT

#123334

Designed for genomic deletion screening of transcription factors by targeting the DNA binding domains.

Christopher Vakoc

Huang et al Genes Dev. 2018 Jul 1;32(13-14):915-928.

May 2, 2019

Academic Institutions and Nonprofits only

#158757-AAV8

Ready-to-use AAV8 particles produced from pAAV-CAG-SomaGCaMP6f2 (#158757). In addition to the viral particles, you will also receive purified pAAV-CAG-SomaGCaMP6f2 plasmid DNA. CAG-driven expression of soma-targeting GCaMP6f2. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Shemesh et al Neuron. 2020 Jun 26. pii: S0896-6273(20)

Feb. 23, 2021

Academic Institutions and Nonprofits only

#130909-AAV8

Ready-to-use AAV8 particles produced from AAV-CAG-FLPX-rc [ChrimsonR-tdTomato] (#130909). In addition to the viral particles, you will also receive purified AAV-CAG-FLPX-rc [ChrimsonR-tdTomato] plasmid DNA. CAG-driven, Flp-dependent expression of ChrimsonR-tdTomato. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Jan. 6, 2022

Academic Institutions and Nonprofits only

#121675-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

Dec. 15, 2020

Academic Institutions and Nonprofits only